and capillary leak syndrome. Microangiopathy, a characteristic form of EC damage associated with severity of GVHD in recipients of allogeneic bone marrow transplants, has To investigate endothelial cell alterations in BMT recipients developing acute graft-versus-host disease been described earlier by our group 1,2 suggesting that not only the epithelium but also EC may be affected in the (aGVHD) we determined levels of the endothelial cell markers von Willebrand factor (VWF) and thrombomcourse of aGVHD. In these studies, von Willebrand factor (VWF) levels odulin (TM) in 57 patients undergoing BMT. Before conditioning VWF and TM levels did not differ signifiwere used as markers of EC damage. VWF can be synthesized and released by EC and is regarded as an indicator cantly between transplant recipients who later developed no or mild (grade I) aGVHD (group A, alloof EC activation or injury. 3 TM which is localized on the surface of EC plays a crucial role in the activation of the geneic n ‫؍‬ 22, autologous n ‫؍‬ 7; VWF 136.0 ؎ 44.1%; TM 29.5 ؎ 18.0 ng/ml), and those with moderate or sevnatural anticoagulant protein C. 4 TM, therefore, is an important factor for the maintenance of the antithrombotic ere (grade II or III) aGVHD (group B, n ‫؍‬ 28; VWF 142.2 ؎ 37.6%; TM 35.2 ؎ 20.1 ng/ml). A first signifiproperties of EC. A soluble form of TM, which probably represents a degradation product of tissue TM, can be cant rise of both VWF and TM levels was noted after conditioning (day 0) both in group A (VWF measured in plasma and represents a reliable marker of EC damage.
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197.0 ؎ 113.3%; P Ͻ 0.001; TM 39.3 ؎ 23.3 ng/ml; P Ͻ 0.01) as well as in group B (VWF 201.7 ؎ 53.3%; P We have now determined VWF and TM levels in the plasma of BMT recipients to evaluate further the possible Ͻ 0.0001; TM 43.5 ؎ 23.5 ng/ml; P Ͻ 0.05). Subgroup analysis of autografted patients revealed no significant association of acute GVHD and endothelial cell injury. increase after conditioning in these patients. At the time of engraftment and onset of aGVHD (day 21), when VWF and TM levels within the groups were signifiPatients, materials and methods cantly elevated as compared with baseline (day −8) levels, group B patients (62.7 ؎ 38.5 ng/ml) had signifiFifty-seven patients (mean age 37.1 Ϯ 10.2 years; range from 16 to 58 years; 25 female, 32 male) suffering from cantly higher (P Ͻ 0.01) TM levels than patients of group A (37.4 ؎ 19.6 ng/ml). This significant elevation hematologic diseases were studied. Diagnoses included AML (n = 18), ALL (n = 9), CML (n = 26), lymphoma (n also persisted at the end of the investigational period (day 28; group B: 56.0 ؎ 37.6 ng/ml; group A:
= 2), multiple myeloma (n = 1), and SAA (n = 1). Fifty patients received allogeneic transplants (33 from related, 17 38.2 ؎ 23.7 ng/ml; P Ͻ 0.01). An elevation of endothelial cell markers is found in the course of BMT, particularly from unrelated donors), seven patients autologous transplants. The following conditioning regimens were used: after conditioning and at the time of engraftment. This increase is pronounced in patients with aGVHD suggest-TBI/Cy4 (total body irradiation 3 × 4 Gy in 3 days/cyclophosphamide 200 mg/kg in 4 days) n = 21, ing not only epithelial cell but also endothelial cell injury during aGVHD.
Bu4/Cy4 (busulphan 16 mg/kg in 4 days) n = 18, Bu4 n = 5, TBI/VP-16 (60 mg/kg in 1 day) n = 5, Bu4/Cy2 Keywords: von Willebrand factor; thrombomodulin; graft-versus-host disease; endothelium (cyclophosphamide 120 mg/kg in 2 days) n = 4, CVB (cyclophosphamide 6 g/m 2 in 4 days, BCNU 300 mg/m 2 in 1 day, VP-16 600 mg/m 2 in 3 days) n = 2, TBI/Cy2 n = 1, Cy4 n = 1. In allogeneic BMT, cyclosporine (CsA) and a Endothelial cells (EC) play a pivotal role in major transshort course of MTX were used as prophylaxis for GVHD. plant-related complications. According to the present state Citrated blood samples (3.8% sodium citrate 9:1) were of knowledge, injury of EC is involved in the pathogenesis collected in a standardized manner between 7 and 8 a.m. of hepatic veno-occlusive disease, sepsis, microangiopathy on the morning before (day −8) conditioning, before BMT (day 0) and afterwards weekly (days 7-28). Samples were cooled immediately after collection (4°C) and centrifuged assays (ELISA) using monoclonal antibodies (Asserachrom Following BMT vWF, Diagnostica Stago, Asnieres, France/Boehringer Endothelial cell activation, as indicated by a significant rise Mannheim, Mannheim, Germany; Asserachrom Thromin VWF and TM levels, was noted in both groups. No sigbomodulin, Diagnostica Stago).
nificant differences were observed in post-transplant levels Acute GVHD was graded clinically according to the criof VWF and TM between group A subgroups of allogeneic teria of Glucksberg et al. 9 The following groups were diftransplant recipients with either no or mild aGVHD and ferentiated: group A: patients without or with mild (grade patients receiving autologous transplants. I) acute GVHD (n = 29; autografted n = 7; allografted n = VWF levels following BMT (day 7-28) were signifi-22; related donor n = 17; unrelated donor n = 5) and group cantly elevated in both group A and group B at all time-B: allogeneic transplant recipients with moderate or severe points between days 7 and 28 as compared to baseline (day acute GVHD (n = 28; grade II: n = 20, grade III: n = 8; −8) levels (Figure 1 ). related donor n = 16; unrelated donor n = 12) requiring TM levels in the 28 group B patients were significantly corticosteroid and other immunosuppressive therapy.
elevated at all time-points between days 7 and 28 as comThe Wilcoxon matched pairs test was used to determine pared to the pretransplant level, whereas in group A this differences within the groups at several time-points comelevation was statistically significant only on day 21 pared with baseline levels. The Mann-Whitney U test was (Figure 2 ). used to assess differences between several groups at corresponding time-points. Graphs show medians, and individual VWF and TM levels at each time-point.
Comparing patients of group A and B at corresponding post-transplant time-points
VWF levels did not differ significantly between days 7 and Results
(Figure 1). Subgroups of group B with moderate (grade Before conditioning
II, n = 20) and severe (grade III, n = 8) aGVHD also revealed no significant differences as compared with No significant differences existed between VWF and TM patients of group A (Table 1) . levels of patients developing no or mild aGVHD (group A)
In contrast, TM levels on day 21, which represented the and patients developing moderate or severe aGVHD first determination after engraftment as well as the onset of (group B).
GVHD in 22 out of 28 group B patients, were significantly higher (P Ͻ 0.01) in group B as compared with group A After conditioning patients. Further analysis of subgroups confirmed this finding. Group B patients with moderate as well as severe At the time of BMT (day 0) both VWF and TM levels were significantly elevated in group A (VWF P Ͻ 0.001; TM P GVHD had significantly higher TM levels on day 21 than group A patients (P Ͻ 0.01 and P Ͻ 0.05, respectively). Ͻ 0.01) and B (VWF P Ͻ 0.0001; TM P Ͻ 0.05) as compared to baseline levels on day −8 (Figures 1 and 2) . How-
The direct comparison between patients with moderate and severe GVHD revealed no significant difference (Table 2) . ever, subgroup analysis of autologous transplant recipients revealed no significant rise of VWF and TM when comparAs shown in Figure 2 this elevation of TM levels in group B patients also persisted at the end of the investiing levels before (day −8) and after (day 0) conditioning. In addition, on day 0 VWF levels of autografted patients gational period (day 28) when significantly higher levels were measured in group B patients (P Ͻ 0.01) as well as were significantly lower than those of allografts with no or only mild aGVHD (P Ͻ 0.05) and those with moderate or in subgroups (Table 2 ) with moderate (P Ͻ 0.05) and severe (P Ͻ 0.05) aGVHD compared with group A patients. severe aGVHD (P Ͻ 0.01; Tables 1 and 2). On day 0 VWF levels of autografted patients were significantly lower than those of other subgroups ( # P Ͻ 0.05; ## P Ͻ 0.01). *Denotes significant elevation of VWF within the group at the corresponding time-point compared with baseline levels on day −8 (*P Ͻ 0.05; **P Ͻ 0.01). On day 21 representing the time of engraftment and onset of aGVHD in 22 of 28 group B patients those had significantly higher TM levels than group A patients. This elevation persisted on day 28 ( # P Ͻ 0.05; ## P Ͻ 0.01). *Denotes significant elevation of TM within the group at the corresponding time-point compared with baseline levels on day −8 (*P Ͻ 0.05; **P Ͻ 0.01). 
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Figure 1 VWF levels (%) in BMT recipients with and without a GVHD. VWF levels were determined before conditioning (day −8), before BMT (day 0) and weekly afterwards (days 7 to 28). ᮍᮍ (group A, patients with no or only mild GVHD I, n =29) and ᮏᮏ (group B, patients with moderate (II, n = 20) or severe (III, n = 8) GVHD, n = 28) denote a significant (P Ͻ 0.01) elevation of VWF at the corresponding time-point compared with baseline levels on day −8. Bars indicate medians.̃= TBI/ć = no TBI during conditioning. Both VWF and TM levels within group B were signifiof 4 Gy results in significant programmed cell death 13 which might be responsible for the release of endothelial cantly elevated (P = 0.0001) at the peak expression of aGVHD within the investigational period as compared with cell markers. During the early post-transplant period (days 7 and 14) the levels before conditioning. No significant difference existed between subgroups with moderate and severe patients presented with a different pattern of EC markers. In contrast to the persistent significant elevation of VWF aGVHD at the time-point of aGVHD maximum. levels in both groups indicating EC perturbation, TM levels during this period were significantly elevated only in group B, not in group A. It can be speculated that an enhanced Discussion acute phase reactivity of VWF may have contributed to this phenomenon. Our data reveal at least three phases of endothelial cell activation in the course of BMT. The first significant increase General elevations of VWF levels following BMT have also been described by others.
14 Though it was concluded of both VWF and TM levels in allogeneic transplants after conditioning was in contrast to the constant levels in autothat the post-transplant rise in VWF was not primarily due to an acute phase response, the concomitant C-reactive prologous transplant recipients at that time-point. This observation suggests a role of CsA-associated EC toxicity, as tein increase in the first 2 weeks after BMT suggests a possible acute phase contribution to VWF enhancement in the CsA-induced time-and concentration-dependent damage of cultured EC has already been demonstrated. A second phase of pronounced EC damage was revealed Alternatively, this difference between autologous and allogeneic transplants might reflect the different intensities on day 21, which represented the first determination after engraftment as well as after onset of aGVHD symptoms in of the conditioning regimens used, since five out of seven patients receiving autologous marrow were conditioned the majority of group B patients. Alterations reflected by significantly enhanced VWF and TM levels were demonwith busulfan only whereas 49 of 50 allogeneic transplant recipients received radiochemotherapy or combination strated in patients both with and without aGVHD and point to a mechanism linked to engraftment. The report of a rise chemotherapy regimens. Irradiation and chemotherapy can damage endothelial cells. 11, 12 Our group has recently shown in the level of VWF at the time of engraftment in a syngeneic transplant recipient supports this theory.
14 that irradiation of human endothelial cells even at a dose Enhanced procoagulant activity of repopulating monobe cleared predominantly by the kidneys and the liver 22 it has to be noted that no significant differences in kidney cytes as well as increased cytokine production have been observed during the period of engraftment and might confunction existed between the groups and no patient suffered from acute liver failure during the investigational period. tribute to enhanced EC activation independent of aGVHD. We were recently able to demonstrate enhanced EC
In conclusion, the results demonstrate that EC damage is present in BMT recipients and is pronounced in patients apoptosis in coculture experiments of irradiated EC and native peripheral blood mononuclear cells which could be with acute GVHD. Further investigation of the interaction between conditioning, aGVHD and EC damage should lead explained by membrane bound TNF␣ and other soluble factors released by these cells. 13 These in vitro data suggest not only to a reduction of acute endothelial complications but also help prevent long-term toxicity following BMT. that cellular reconstitution may contribute toward increased EC activation in the setting of BMT.
Our results demonstrating no significant increase of TM levels within the autologous subgroup are in agreement
